{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:53Z","timestamp":1791237833430,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Tripartite motif-containing 21 (TRIM21) is a cytoplasmic protein with E3 ubiquitin ligase activity. Although autoantibodies against TRIM21 are frequently detected in patients with systemic lupus erythematosus (SLE), its role in disease pathogenesis remains unclear. Here we demonstrate that TRIM21 directly interacts with the stimulator of interferon genes (STING) to regulate type I interferon (IFN) production. In both induced and spontaneous murine models of lupus, TRIM21 deficiency exacerbated lupus-like pathology and heightened IFN production after STING activation. By contrast, TRIM21 overexpression attenuated autoimmunity in lupus-prone mice. Mechanistically, TRIM21 binds to STING and promotes its degradation via the ubiquitin\u2013proteasome pathway. In patients with SLE, TRIM21 expression levels inversely correlated with STING expression, type I IFN levels and autoantibody titers. These findings suggest that targeting the TRIM21\u2013STING axis may offer a therapeutic strategy to reduce type I IFN production in SLE.<\/jats:p>","DOI":"10.1038\/s12276-025-01490-5","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:16:40Z","timestamp":1751519800000},"page":"1555-1566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The ubiquitin E3 ligase TRIM21 suppresses type I interferon signaling via STING degradation and ameliorates systemic autoimmunity"],"prefix":"10.1038","volume":"57","author":[{"given":"Da Som","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5715-3989","authenticated-orcid":false,"given":"Mi-La","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-8364","authenticated-orcid":false,"given":"Seung-Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2, 16039 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110\u20132121 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","volume":"25","author":"J Banchereau","year":"2006","unstructured":"Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383\u2013392 (2006).","journal-title":"Immunity"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta, M. et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 1909\u20131916 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011\u20131019 (2023).","journal-title":"Lancet"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.4049\/jimmunol.1501157","volume":"195","author":"X Liao","year":"2015","unstructured":"Liao, X. et al. Cutting edge: plasmacytoid dendritic cells in late-stage lupus mice defective in producing IFN-\u03b1. J. Immunol. 195, 4578\u20134582 (2015).","journal-title":"J. Immunol."},{"key":"1490_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19918-z","volume":"11","author":"A Psarras","year":"2020","unstructured":"Psarras, A. et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat. Commun. 11, 6149 (2020).","journal-title":"Nat. Commun."},{"key":"1490_CR9","first-page":"575","volume":"18","author":"A Psarras","year":"2022","unstructured":"Psarras, A., Wittmann, M. & Vital, E. M. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat. Rev. Rheumatol. 18, 575\u2013590 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","volume":"13","author":"T Kawai","year":"2006","unstructured":"Kawai, T. & Akira, S. TLR signaling. Cell Death Differ. 13, 816\u2013825 (2006).","journal-title":"Cell Death Differ."},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","volume":"25","author":"SR Christensen","year":"2006","unstructured":"Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417\u2013428 (2006).","journal-title":"Immunity"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/eji.200838138","volume":"38","author":"AM Fairhurst","year":"2008","unstructured":"Fairhurst, A. M. et al. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur. J. Immunol. 38, 1971\u20131978 (2008).","journal-title":"Eur. J. Immunol."},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548\u2013569 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1490_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101530","volume":"23","author":"A Thim-Uam","year":"2020","unstructured":"Thim-Uam, A. et al. STING mediates lupus via the activation of conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation. iScience 23, 101530 (2020).","journal-title":"iScience"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3389\/fimmu.2019.02049","volume":"10","author":"S Foss","year":"2019","unstructured":"Foss, S. et al. TRIM21\u2014from intracellular immunity to therapy. Front. Immunol. 10, 2049 (2019).","journal-title":"Front. Immunol."},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.autrev.2021.103013","volume":"21","author":"P Decker","year":"2022","unstructured":"Decker, P. et al. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun. Rev. 21, 103013 (2022).","journal-title":"Autoimmun. Rev."},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1084\/jem.20090585","volume":"206","author":"A Espinosa","year":"2009","unstructured":"Espinosa, A. et al. Loss of the lupus autoantigen Ro52\/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23\u2013Th17 pathway. J. Exp. Med. 206, 1661\u20131671 (2009).","journal-title":"J. Exp. Med."},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2020.00098","volume":"11","author":"Y Kunishita","year":"2020","unstructured":"Kunishita, Y. et al. TRIM21 dysfunction enhances aberrant B-cell differentiation in autoimmune pathogenesis. Front. Immunol. 11, 98 (2020).","journal-title":"Front. Immunol."},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ni.2492","volume":"14","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z. et al. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat. Immunol. 14, 172\u2013178 (2013).","journal-title":"Nat. Immunol."},{"key":"1490_CR20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.celrep.2019.09.069","volume":"29","author":"D Li","year":"2019","unstructured":"Li, D. et al. STING-mediated IFI16 degradation negatively controls type I interferon production. Cell Rep. 29, 1249\u20131260 (2019).","journal-title":"Cell Rep."},{"key":"1490_CR21","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","volume":"171","author":"D Clift","year":"2017","unstructured":"Clift, D. et al. A method for the acute and rapid degradation of endogenous proteins. Cell 171, 1692\u20131706 (2017).","journal-title":"Cell"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-017-1402-1","volume":"19","author":"YY Kim","year":"2017","unstructured":"Kim, Y. Y. et al. HM71224, a selective Bruton\u2019s tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res. Ther. 19, 211 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"1490_CR23","first-page":"271694","volume":"2011","author":"D Perry","year":"2011","unstructured":"Perry, D., Sang, A., Yin, Y., Zheng, Y. Y. & Morel, L. Murine models of systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 271694 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"1490_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.38298","volume":"66","author":"M Yokogawa","year":"2014","unstructured":"Yokogawa, M. et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic lupus erythematosus. Arthritis Rheumatol. 66, 694\u2013706 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1490_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2010.11.012","volume":"143","author":"MJ Clague","year":"2010","unstructured":"Clague, M. J. & Urb\u00e9, S. Ubiquitin: same molecule, different degradation pathways. Cell 143, 682\u2013685 (2010).","journal-title":"Cell"},{"key":"1490_CR26","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u2013291 (2002).","journal-title":"J. Rheumatol."},{"key":"1490_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O\u2019Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87\u2013103 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1490_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","volume":"14","author":"MK Crow","year":"2019","unstructured":"Crow, M. K., Olferiev, M. & Kirou, K. A. Type I interferons in autoimmune disease. Annu. Rev. Pathol. 14, 369\u2013393 (2019).","journal-title":"Annu. Rev. Pathol."},{"key":"1490_CR29","doi-asserted-by":"publisher","first-page":"738473","DOI":"10.3389\/fimmu.2021.738473","volume":"12","author":"EL Jones","year":"2021","unstructured":"Jones, E. L., Laidlaw, S. M. & Dustin, L. B. TRIM21\/Ro52\u2014roles in innate immunity and autoimmune disease. Front. Immunol. 12, 738473 (2021).","journal-title":"Front. Immunol."},{"key":"1490_CR30","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","volume":"181","author":"R Higgs","year":"2008","unstructured":"Higgs, R. et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J. Immunol. 181, 1780\u20131786 (2008).","journal-title":"J. Immunol."},{"key":"1490_CR31","doi-asserted-by":"publisher","first-page":"e11776","DOI":"10.1371\/journal.pone.0011776","volume":"5","author":"R Higgs","year":"2010","unstructured":"Higgs, R. et al. Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral toll-like receptors. PLoS ONE 5, e11776 (2010).","journal-title":"PLoS ONE"},{"key":"1490_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/art.40002","volume":"69","author":"J An","year":"2017","unstructured":"An, J. et al. Expression of cyclic GMP-AMP synthase in patients with systemic lupus erythematosus. Arthritis Rheumatol. 69, 800\u2013807 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1490_CR33","doi-asserted-by":"publisher","first-page":"E710","DOI":"10.1073\/pnas.1420217112","volume":"112","author":"S Sharma","year":"2015","unstructured":"Sharma, S. et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc. Natl Acad. Sci. USA 112, E710\u2013E717 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1490_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103314","volume":"66","author":"T Prabakaran","year":"2021","unstructured":"Prabakaran, T. et al. A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology. EBioMedicine 66, 103314 (2021).","journal-title":"EBioMedicine"},{"key":"1490_CR35","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1172\/JCI114052","volume":"83","author":"LA Lee","year":"1989","unstructured":"Lee, L. A., Gaither, K. K., Coulter, S. N., Norris, D. A. & Harley, J. B. Pattern of cutaneous immunoglobulin G deposition in subacute cutaneous lupus erythematosus is reproduced by infusing purified anti-Ro (SSA) autoantibodies into human skin-grafted mice. J. Clin. Invest. 83, 1556\u20131562 (1989).","journal-title":"J. Clin. Invest."},{"key":"1490_CR36","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/archderm.1994.01690100046006","volume":"130","author":"LA Lee","year":"1994","unstructured":"Lee, L. A., Roberts, C. M., Frank, M. B., McCubbin, V. R. & Reichlin, M. The autoantibody response to Ro\/SSA in cutaneous lupus erythematosus. Arch. Dermatol. 130, 1262\u20131268 (1994).","journal-title":"Arch. Dermatol."},{"key":"1490_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","volume":"32","author":"S Narain","year":"2020","unstructured":"Narain, S., Berman, N. & Furie, R. Biologics in the treatment of Sjogren\u2019s syndrome, systemic lupus erythematosus, and lupus nephritis. Curr. Opin. Rheumatol. 32, 609\u2013616 (2020).","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01490-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:41:12Z","timestamp":1757205672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01490-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01490-5","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}